Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study
Authors' conclusion
In this real-world study of patients in the T1DX-QI Collaborative, CGM users had better glycemic control and lower rates of DKA and severe hypoglycemia (SH) events, compared to nonusers; however, there were significant sociodemographic disparities in CGM use. Quality improvement and advocacy measures to promote widespread and equitable CGM uptake have the potential to improve clinical outcomes.
Study context
- Population
- T1D patients at eight US endocrinology clinics in the T1DX-QI Collaborative, 2017–2019
- Participants
- 11,469 patients
- Exposure
- Continuous Glucose Monitoring (CGM) users vs nonusers
- Outcome
- CGM use
Methodological detailsreal-world, electronic health record data, multicentre
- Real-world
- Electronic health record data
- Multicentre
Main finding
As reported in the abstract
- CGM users
- 48%
- CGM use, Non-Hispanic Whites
- 50%
- CGM use, Non-Hispanic Blacks
- 18%
- CGM use, Hispanics
- 38%
- CGM use, private insurance
- 57.2%
- CGM use, public insurance (incl. Medicaid or Medicare)
- 33.3%
Observational data: associations, not effects.
Further findings
HbA1c
Diabetic ketoacidosis (DKA) and severe hypoglycemia
- Rates of DKA and severe hypoglycemia significantly higher in nonusers vs CGM users
Original publication
Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study. J Diabetes Sci Technol. Published 9 October 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →